Practical solutions – from the front door to the back office
Canopy connects and automates workflows across all patient services.
Canopy is Enterprise AI for Oncology
For oncology, by oncology.
Exclusively trained with oncology data across the patient journey.
AI that works with you, not instead of you.
Spend more time on what you’re best at, not chasing new systems or information.
Built for how oncology works
Trusted in the most important moments.
Built for the complexity of oncology interactions and therapies.
"...Our nurses were spending 50% of their time being nurses and 50% of their time on the administrative burden... we've made significant progress toward our target of 80%/20%"
Dr. Debra Patt
Executive Vice President of Public Policy and Strategy, Texas Oncology
93% faster resolution of patient requests.
Source: Internal analysis of practice use of Canopy software
"Through Canopy, we are revolutionizing our operations to ensure seamless delivery of care and equipping patients with digitally inclusive tools. This empowers them to effectively communicate their symptoms and concerns anytime and anywhere, further enhancing their healthcare experience."
Dr. Jeff Vacirca
CEO, New York Cancer & Blood Specialists, and Co-Founder, OneOncology
22% fewer ER visits, with less disruption to care.
Source: Kolodziej et al., J Clin Oncol. 2022;40(16_suppl):1508.
"With Canopy’s support, we’ve integrated ePROs with AI-native triage tools and programs like CCM and RTM to build a sustainable model that improves outcomes, eases staff workload, and generates revenue to reinvest in care. Today, more than half of our patients on qualifying treatment are enrolled."
Jeff Hunnicutt
CEO, Highlands Oncology
4x increase in annual revenue that supports between visit care.
Source: Internal analysis of practice use of Canopy software
RESULT
Up to 45% of patients stayed on treatment at 3 months with Canopy ePRO monitoring
Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting.
RESULT
Canopy ePRO surfaced more AEs in near real-time for chemo and bispecific regimens
Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
RESULT
In aMel, pembrolizumab alone was tied to fewer symptoms than nivolumab and ipilimumab
Electronic patient-reported outcomes (ePRO) in patients with advanced melanoma receiving immune checkpoint inhibitors: Insights from the Canopy ePRO system.